Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes

(2013) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells

(2013) Y Wei et al.   LEUKEMIA

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

(2012) S Anguille et al.   LEUKEMIA

Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes

(2012) Hetty J. Bontkes et al.   LEUKEMIA RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Th17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes

(2011) Irene Bouchliou et al.   CLINICAL IMMUNOLOGY

Impact of the hypomethylating agent 5-azacytidine on dendritic cells function

(2011) Jihane Frikeche et al.   EXPERIMENTAL HEMATOLOGY

Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers

(2011) Sébastien Anguille et al.   Human vaccines & immunotherapeutics

Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells

(2011) Ben Youngblood et al.   IMMUNITY

Targeting Immune Dysregulation in Myelodysplastic Syndromes

(2011) Matthew J. Olnes   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Interferon-α in acute myeloid leukemia: an old drug revisited

(2011) S Anguille et al.   LEUKEMIA

Myelodysplastic syndromes: the role of the immune system in pathogenesis

(2011) Erica D. Warlick et al.   LEUKEMIA & LYMPHOMA

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

(2011) Zhen Zeng et al.   PLoS One

Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes

(2011) Tapan M. Kadia et al.   SEMINARS IN ONCOLOGY

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

(2010) Elias Jabbour et al.   CANCER

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

(2009) R. Karim et al.   CLINICAL CANCER RESEARCH

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Myelodysplastic Syndromes

(2009) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Myelodysplastic syndromes

(2008) S. D. Nimer   BLOOD

Clinical significance of regulatory T cells in patients with myelodysplastic syndrome

(2008) Wedad Hamdi et al.   EUROPEAN JOURNAL OF HAEMATOLOGY